Difference between revisions of "Physician Scorecards"
From PatientRecovery
Line 1: | Line 1: | ||
− | * | + | * Care Variations |
− | * | + | * Surgery |
− | * | + | * Inpatient Admissions |
− | * | + | * Episode Treatment Groups (ETGs) Performance |
− | * | + | * Advanced BPCI |
− | * | + | * Patient Risk Adjustment |
− | * | + | * HCCs – Suspect HCCs and Dropped HCCs |
− | * | + | * Patient Predictive Analytics (i.e., ER in 3 months) |
+ | * Patient Per-Member-Per-Month (PMPM) | ||
+ | * Leakage (referrals, poorly managed patients in competitors ER, Inpatient) | ||
+ | * Ambulatory Care Sensitive Admissions or ER Visits | ||
+ | * Generic vs. Brand Name drugs | ||
+ | * Site of Services | ||
+ | * Choosing Wisely Diagnostic Tests and Treatments | ||
+ | * Care Gaps and HEDIS Measures | ||
+ | * Medicare Advantage Incentives Opportunities (i.e., $200 per patient vs. $500) | ||
Back to [[Physician Engagement]] | Back to [[Physician Engagement]] | ||
Back to [[Growth & Value Strategies]] | Back to [[Growth & Value Strategies]] |
Revision as of 14:54, 19 February 2019
- Care Variations
- Surgery
- Inpatient Admissions
- Episode Treatment Groups (ETGs) Performance
- Advanced BPCI
- Patient Risk Adjustment
- HCCs – Suspect HCCs and Dropped HCCs
- Patient Predictive Analytics (i.e., ER in 3 months)
- Patient Per-Member-Per-Month (PMPM)
- Leakage (referrals, poorly managed patients in competitors ER, Inpatient)
- Ambulatory Care Sensitive Admissions or ER Visits
- Generic vs. Brand Name drugs
- Site of Services
- Choosing Wisely Diagnostic Tests and Treatments
- Care Gaps and HEDIS Measures
- Medicare Advantage Incentives Opportunities (i.e., $200 per patient vs. $500)
Back to Physician Engagement
Back to Growth & Value Strategies